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D ialysis therapy for patients with severe hypona-tremia is challenging because rapid correction of
the serum sodium concentration may lead to osmotic
demyelination syndrome (ODS).1 Gradual correction of
hyponatremia is recommended to prevent hazardous
sequelae.2,3 Continuous venovenous hemoﬁltration
(CVVH) with low-sodium replacement solution can be
used to prevent rapid correction of the serum sodium
concentration;4 however, preparation of low-sodium
replacement solution by dilution is difﬁcult and is
not recommended. We developed the “FlexNa”
method, which involves ﬂexible adjustment of the
sodium concentration of commercially available
replacement ﬂuid; it assures provision of CVVH without
affecting the patient’s serum sodium concentration. We
present a case of acute kidney injury concomitant with
severe hyponatremia and hyperkalemia, which was
treated successfully with CVVH using this FlexNa
method.
CASE PRESENTATION
A 46-year-old woman presented to the emergency
department with confusion and dysarthria for
12 hours. She had experienced decreased oral intake fors the English translation of a Japanese article by the same
rs published in the Journal of Japan Society for Blood Pu-
ion in Critical Care (http://jsbpcc.umin.jp/). Reprinted with
ssion from Igaku-tosho Shuppan Co., Ltd.
International Reports (2016) 1, 85–881 week, but had refused to visit a hospital. She had
been hospitalized due to symptomatic hyponatremia a
few months previously. Her past medical history
included anorexia nervosa and chronic tubulointer-
stitial nephritis. Vital signs were as follows: systolic
blood pressure, 70 mm Hg; heart rate, 60 beats per
minute; respiration rate, 24 breaths per minute; and
pulse oximetry, 100% on room air. Her body weight on
admission was 33 kg.
A review of systems showed decreased urinary
output. Serum laboratory studies showed the following
values: sodium, 99 mEq/l; potassium, 7.7 mEq/l; chlo-
ride, 63 mEq/l; bicarbonate, unmeasurable; serum urea
nitrogen, 184.5 mg/dl; creatinine, 10.69 mg/dl; phos-
phorus, 19.6 mg/dl; uric acid, 21.9 mg/dl; albumin,
2.8 g/dl; and serum osmolality, 291 mOsm/kg. Arterial
blood gas analysis showed a pH of 7.01, PaCO2 of
7.7 mm Hg, PaO2 of 165 mm Hg, and bicarbonate level
of 1.9 mEq/l. The urine osmolality was 292 mOsm/kg
H2O, the sodium level was 29 mEq/l, the potassium
level was 35 mEq/l, the urea nitrogen level was 215
mg/dl, and the creatinine level was 92 mg/dl, with
fractional sodium excretion of 3.1%. An electrocar-
diogram showed peaked T waves and a widened QRS
complex.
The patient was diagnosed with acute kidney injury
due to acute tubular necrosis, severe hypovolemic
hyponatremia, and severe hyperkalemia.
After admission, supportive therapy including
ﬂuid resuscitation and insulin therapy with glucose
and sodium bicarbonate was initiated. The patient’s85
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improved, but she remained anuric and her serum
potassium level exceeded 5.8 mEq/l for 24 hours. The
decision to initiate dialysis therapy was made, but
intermittent hemodialysis or CVVH has the risk of
rapid correction of hyponatremia. To avoid rapid
correction of the serum sodium concentration, we
started CVVH using the 5% dextrose solution (D5W)
infusion method, which we named the FlexNa method.
CVVH using commercially available replacement ﬂuid
(Sublood-BSG; FUSO Pharmaceutical Industries Ltd.,
Tokyo, Japan), which has a sodium concentration of
140 mEq/l, was started with continuous infusion of
D5W to the CVVH circuit after hemoﬁltration. By
using the FlexNa method, we were able to effectively
administer a replacement solution with a sodium
concentration equal to the patient’s serum sodium
concentration, which was 100 mEq/l at the start of
CVVH. This prevented any increase in the serum
sodium attributable to the CVVH. The prescription
of the CVVH was: blood ﬂow, 100 ml/min; replace-
ment ﬂuid, 500 ml/h; and infusion rate of D5W,
200 ml/h. Correction of hyponatremia and hypo-
volemia was achieved by i.v. administration of
sodium bicarbonate solution, which safely raised
the patient’s serum sodium level to 108 mEq/l over
24 hours. After 24 hours of CVVH, her serum
potassium level decreased to 3.6 mEq/l and urine
output was recovered, and CVVH was discontinued
(Figure 1). Thereafter, she received supportive ther-
apy and recovered completely from hyponatremia
and AKI with no neurologic complication. Her serum
sodium concentration at the time of discharge was
143 mEq/l.
This case was presented at the Japan Society for
Blood Puriﬁcation in Critical Care meeting on October
2015 and published in Japanese.5 The patients pro-
vided full informed consent for gathering the data and
publishing the case.Figure 1. Hospital course of the patient.
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Patients with symptomatic hyponatremia with severe
renal failure pose a therapeutic challenge. Severe
hyperkalemia with kidney failure requires dialysis
therapy; however, conventional hemodialysis therapy
involves the risk of ODS due to rapid correction of the
serum sodium concentration ([Naþ]). The FlexNa
method can provide safe, effective, and effortless renal
replacement therapy.
Hyponatremia is associated with increased mortality
and morbidity.6 In patients with chronic hypona-
tremia, brain cells lose organic solutes, which decreases
the risk of life-threatening cerebral edema.1 However,
this adaptation makes the brain more vulnerable to
ODS in response to rapid correction of hyponatremia.7,8
Furthermore, risk factors for the development of
ODS, such as severe hyponatremia (serum [Naþ]
#105 mmol/l), hypokalemia, alcoholism, malnutrition,
and adverse liver disease, must be considered. Guide-
lines recommend that a 5-mEq/l increase in serum [Naþ]
is sufﬁcient to improve symptoms, and the therapeutic
“limits” of the increase in serum [Naþ] are 10 mEq/l in
24 hours and 18 mEq/l in 48 hours.2,3
In contrast, severe hyperkalemia associated with
electrocardiogram changes is a life-threatening condition.
Although severe hypokalemia with kidney failure
requires dialysis therapy, the treatment of hyponatremia
must be performed in parallel when the patient presents
concomitant severe symptomatic hyponatremia. This
condition renders the treatment more complicated in
severe cases of hyponatremia because renal replacement
therapy (intermittent hemodialysis or CVVH) can be
hazardous due to rapid correction. In patients with
severe hyponatremia, intermittent hemodialysis espe-
cially provokes rapid correction of serum sodium con-
centration and puts the patient at risk of ODS.9
The conventional strategy to prevent rapid correc-
tion of serum [Naþ] is to provide CVVH using low-
sodium replacement ﬂuid. Yessayan et al.4 proposed
a sophisticated method to correct hyponatremia grad-
ually using CVVH with low-sodium replacement ﬂuid.
They introduced an equation to modify replacement
ﬂuid [Naþ] according to the desired “target” serum
[Naþ] for the ﬁrst 24 hours. However, Yessayan et al.’s
direct hyponatremia correction method was not used
in our case because the patient seemed to be more
susceptible to ODS due to several risk factors, such as
chronic severe hyponatremia and malnutrition. In
Yessayan et al.’s method, the replacement ﬂuid must
be adjusted to the estimated “target” [Naþ], that is the
“limit” [Naþ] for the correction of hyponatremia,
which is likely to increase the risk of ODS develop-
ment due to the increase in sodium concentration,Kidney International Reports (2016) 1, 85–88
Figure 2. Differences between the conventional and FlexNa
methods. Conventional: Prepare low-[Naþ] replacement fluid (RF) by
diluting standard-[Naþ] bags with 5% dextrose in water (D5W) in the
first continuous venovenous hemofiltration (CVVH). FlexNa: Mix the
D5W and standard-[Naþ] RF bags immediately before infusion of RF
into the V-line chamber. P, pump.
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frequent changes of replacement ﬂuid may be required
if the increase in serum [Naþ] far exceeds or fails to
reach the predicted value. Moreover, preparation of
commercially available replacement ﬂuid by dilution
is not recommended by manufacturers for safety
reasons.
The goal of hyponatremia treatment is improvement
of symptoms, not correction of serum [Naþ] per se.
Dialysis therapy, which does not alter serum [Naþ] but
removes uremic toxins, such as potassium and urea, is
desired. Therefore, providing CVVH using low-sodium
replacement solution while slowly correcting hypona-
tremia by continuous infusion of 3% NaCl or normal
saline is a simple, safe, and effective method (Figure 2).
Addition of D5W to the commercially available
replacement solution enables adjustment of the
replacement ﬂuid [Naþ]; however, when CVVH is
required for several days, repeated preparation of the
modiﬁed replacement ﬂuid is labor intensive. Instead,
we developed the easier and novel FlexNa method,
which uses CVVH with standard replacement ﬂuid and
i.v. D5W infusion to the post-hemoﬁlter CVVH circuit
(Figure 2). By diluting the blood exiting the dialyzer
using D5W, the serum [Naþ] can be easily maintained
at the desired level, which prevents overcorrection of
hyponatremia; this FlexNa method would result in no
change in the patient serum [Naþ], and correction of
hyponatremia is achieved not by CVVH but by i.v.
administration of sodium. The amount of sodium
required for correction of hyponatremia can be esti-
mated using the equation of Edelman et al., Na
deﬁcit ¼ (desired Na concentration – serum Na
concentration)  total body water.10 From this equa-
tion, we can estimate that administration of 1 ml/kg of
3% sodium chloride solution would raise serum Na
concentration by approximately 1 mEq/l.
The main advantage of the FlexNa method is that
replacement ﬂuid [Naþ] can be adjusted to any desired
concentration at any time by increasing or decreasing
the D5W infusion rate. We ﬁxed replacement ﬂuid
[Naþ] to the patient’s serum Na concentration and
corrected hyponatremia by i.v. administration of so-
dium bicarbonate solution; theoretically, the FlexNa
method per se can correct hyponatremia by adjusting
replacement ﬂuid [Naþ] to target serum sodium
concentration.
The rate of ultraﬁltration (Quf) is determined to be
equal to the D5W infusion rate if ﬂuid removal by
CVVH is not necessary. Because commercially available
replacement ﬂuid bags contain physiological sodium
concentrations of 140 mmol/l, the D5W volume to be
infused to any given Quf is calculated using the
following equation:Kidney International Reports (2016) 1, 85–88volume to infuse ðml=hÞ ¼ Quf
¼ ð140 ðmEq=lÞ  serum ½NaþÞ  replacement
fluid flow rate ðQrf : ml=hÞ = serum ½Naþ
For our patient, an adequate renal replacement dose
of 25 ml/kg per hour ﬁltration was provided. Her
serum [Naþ] level was about 100 mEq/l; therefore, the
estimated infusion rate and Quf were 400 ml/h and
1000 ml/h, respectively.
Alternatively, D5W can be infused i.v. using CVVH
with standard replacement ﬂuid, which is theoretically
identical to the FlexNa method because the infused
replacement ﬂuid is diluted in the body and the serum
[Naþ] does not change.
The FlexNa method has several limitations. Treat-
ment risks include hyperglycemia induced by infusion
of D5W, which requires insulin injection. Our patient
required insulin therapy because of hyperglycemia
during CVVH, which fortunately improved the
hyperkalemia. Infusion pump precision is a critical
factor, and serial monitoring of the concentrations of
serum [Naþ] and other electrolytes is mandatory.
CONCLUSION
The FlexNa method is a safe, controllable, and effortless
treatment modality for patients with severe hypona-
tremia requiring CVVH therapy. However, infusion of
D5W for diluting replacement solution leads to hy-
perglycemia. Continuous monitoring of glucose and
serum potassium is needed for this therapy.
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